Pharmacological significance of the species differences in bupropion metabolism
- 1 January 1987
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 17 (3) , 287-298
- https://doi.org/10.3109/00498258709043939
Abstract
Bupropion provided a dose-dependent prevention of tetrabenazine-induced sedation in mice but not rats. Bupropion was extensively metabolized in mice, rats, dogs and man. About 85% of the dose was excreted in urine of rats and man. The predominant metabolites in rat urine were side chain cleavage products of bupropion (m-chlorobenzoic acid) with a minor fraction consisting of basic side chain hydroxylated metabolites. Mice, dogs and man form a major side chain hydroxylated product (BW 306U) which appeared in higher concentration than bupropion in plasma of these species but not rats. The relatively high plasma levels of BW 306U in mice but not rats may account for the species difference in pharmacological response observed with bupropion.Keywords
This publication has 4 references indexed in Scilit:
- Determination of Bupropion and Its Major Basic Metabolites in Plasma by Liquid Chromatography With Dual-Wavelength Ultraviolet DetectionJournal of Pharmaceutical Sciences, 1984
- Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjectsEuropean Journal of Clinical Pharmacology, 1981
- Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin™)Drug Development Research, 1981
- Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agentJournal of Pharmacy and Pharmacology, 1977